Retrovirus Epidemiology Donor Study-II (REDS II) Molecular Surveillance (MS) - Catalog
Retrovirus Epidemiology Donor Study-II (REDS II) Molecular Surveillance (MS)
HLB00961212a
REDS II-MS
False
True
False
Not Applicable (Data Only)
False
Epidemiology Study
Open BioLINCC Study
Adult
2012-11-19
2012-11-19
2012-11-16
2019-05-10
2006 - 2009
DBDR
Transfusion Medicine
HIV
non-COVID
0
0
No
No
Not Applicable (Data Only)
Not Applicable (Data Only)
Not Applicable (Data Only)
Not Applicable (No Genetic Use Specimens)
Acquired Immunodeficiency Syndrome
Blood Donors
Blood Transfusion
HIV Infections
HIV-1
HIV-2
HTLV-I
HTLV-II
Hepacivirus
Hepatitis B
Hepatitis, Viral, Human
Retroviridae Infections
West Nile Virus
The objective of the study was to conduct a genetic analysis of incident and prevalent strains of HIV, HCV and HBV by testing blood specimens from HIV, HCV or HBV positive blood donors who gave blood at REDS-II centers, as well as at UBS, NYBC and ARC blood centers between 2006 and 2009.
Genetic variations of human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) can affect diagnostic assays and therapeutic interventions. Recent changes in prevalence of subtypes/genotypes and drug/immune-escape variants were characterized by comparing recently infected vs. more remotely infected blood donors.
This study included qualifying donations from 1 January 2006 through 31 December 31 2009 from 3 Retrovirus Epidemiology Donor Study-II (REDS-II) blood centers (Blood Centers of the Pacific, Blood Center of Wisconsin, and Hoxworth Blood Center/University of Cincinnati), all American Red Cross Blood Services regions, United Blood Services regions and the New York Blood Center. Together, these centers account for approximately 70% of the US blood supply.
Infected donors were identified among approximately 34 million US blood donations, 2006–2009 based on screening and confirmatory tests for HIV and HCV nucleic acid testing, HIV and HCV antibody, HBsAg, and anti-HBV core antibody; incident infections were defined as having no or low antiviral antibody titers. Viral genomes were partially sequenced.
Viral genetic variant distribution in blood donors was similar to that seen in high-risk US populations. Blood-borne viruses detected through large-scale routine screening of blood donors can complement molecular surveillance studies of highly exposed populations. (Delwart et. al. 2012)
The study population available in BioLINCC study data may be lower than total study enrollment due to Informed Consent restrictions and other factors.
-
Subjects
12118
Last Modified: July 28, 2014, 2:40 p.m. -
Age
Frequency
Percent
16-20
1442
11.90
21-25
897
7.40
26-30
877
7.24
31-35
815
6.73
36-40
1038
8.57
41-45
1429
11.79
46-50
2002
16.52
51-55
1856
15.32
56-60
1035
8.54
61-65
379
3.13
66-70
179
1.48
71-75
93
0.77
76-80
49
0.40
81-85
16
0.13
>=86
11
0.09
Last Modified: Aug. 25, 2015, 4:04 p.m. -
Sex
Frequency
Percent
NOT AVAILABLE
3
0.02
FEMALE
4366
36.03
MALE
7749
63.95
Last Modified: Aug. 25, 2015, 4:04 p.m. -
Race
Frequency
Percent
REFUSED
4
0.03
NOT AVAILABLE
2621
21.63
ASIAN
966
7.97
BLACK
1823
15.04
HISPANIC
918
7.58
NATIVE AMERICAN
91
0.75
WHITE
5352
44.17
MORE THAN ONE RACE
57
0.47 OTHER
286
2.36
Last Modified: March 11, 2016, 2:48 p.m.